Download our Cleanroom CatalogDownload
Biotech Cleanroom for Allergy Immunotherapy
More than 50 million Americans suffer from allergies every year, from minor allergic rhinitis (hay fever) to life-threatening anaphylactic shock. Allergies cost billions of dollars every year for treating symptoms, and the desensitization protocol is a long process that spans over 3 to 5 years with mixed results.
Biotech companies work on delivering a lasting and permanent solution thanks to allergy immunotherapy treatments. This client provides a unique vaccine platform that emerges from synthetic biology. Their self-adjuvant vector has shown promise in the preclinical stage and has exhibited the possibility of overturning allergy symptoms and side effects.
What started as a vaccine platform for curing allergies could be used to treat other diseases. The vaccine platform could find other applications such as delivering therapeutics in oncology for cancer treatment, supporting immunization efforts against infectious diseases and treating multiple autoimmune disorders.
Biotechnology companies must meet current Good Manufacturing Practices (cGMP) to ensure quality and safety for consumers. Maintenance and calibration of the equipment, employees with proper qualifications, and most importantly, the cleanroom facility construction and activities must all be conducted under the cGMP guidelines.
Biotech products need to be sterile to be administered to the patients, and contamination would be a catastrophe, business-wise. There are many things to consider when choosing a cleanroom provider. For example, if you think about the GMP requirements and cleanliness level, here are a few things to think about:
If you want to learn more about designing a biotech cGMP cleanroom, you can look at our articles: designing a cGMP cleanroom for cell and gene therapy or our cleanroom design checklist.